GSK Receives FDA Accelerated Approval for Jemperli (dostarlimab-gxly) for Adult Patients with Mismatch Repair-Deficient (dMMR) Recurrent or Advanced Solid Tumors
17 August 2021
Second FDA approved indication for dostarlimab in 2021
GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumors
95% of responders had a duration of response of≥6 months
GlaxoSmithKline (GSK) plc...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news